Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.

摘要: Small intestinal bacterial overgrowth (SIBO) affects up to 60% of patients with systemic sclerosis (SSc), and it improves antibiotics. The addition probiotics could lead better results. To evaluate the efficacy safety Saccharomyces boulardii (SB) versus metronidazole (M) M + SB for 2 months, reduce gastrointestinal symptoms SIBO assessed hydrogen breath test in SSc. An open pilot clinical trial performed forty SSc (ACR-EULAR 2013) who signed informed consent. Three groups were assigned: M, SB, M + SB, 2 months. Hydrogen was measured parts per million a SIBO. National Institutes Health Patient-Reported Outcomes Measurement Information System (NIH-PROMIS) questionnaire applied quantify raw score eight symptoms. This study is registered ClinicalTrials.gov following ID: NCT03692299. Baseline characteristics similar between groups. average age 53.2 ± 9.3 years, evolution 13.5 (1–34) years. After 2 months treatment, eradicated 55% group: 33% 25% M. SB had decreased diarrhea, abdominal pain, gas/bloating/flatulence, but M remained unchanged. Reductions expired at 45 60 min as follows: 48% 44%, 18% 20%, 53% first second months, respectively (p < 0.01). Adverse effects epigastric burning constipation (53%) (36%), flatulence/diarrhea (22%). Metronidazole treatment partially effective SIBO, S. monotherapy or combination outcomes